<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770523</url>
  </required_header>
  <id_info>
    <org_study_id>C-004</org_study_id>
    <nct_id>NCT00770523</nct_id>
  </id_info>
  <brief_title>Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells</brief_title>
  <official_title>Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cooperative Study Group A for Hematology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cooperative Study Group A for Hematology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning
      for Younger Patients with Hematologic Malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary end points are treatment-related mortality and engraftment. Secondary end points are
      regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>treatment-related mortality and engraftment</measure>
    <time_frame>all cause mortality</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival.</measure>
    <time_frame>Time point(s) at which outcome measure is assessed.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">52</enrollment>
  <condition>HEMATOLOGIC MALIGNANCIES</condition>
  <eligibility>
    <study_pop>
      <textblock>
        acute leukemia chronic myelogenous leukemia myelodysplastic syndrome
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients should have an unrelated donor who is matched for HLA-A and -B by serology and
        for -DRB1 by molecular typing.

        Exclusion Criteria:

          -  Patients should not have major illness or organ failure

          -  Patients must not have a psychiatric disorder or mental deficiency severe as to make
             compliance with the treatment unlike, and making informed consent impossible.

          -  Patients must not be pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoo-hyung Lee, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>COSAH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yae-Eun Jang</name_title>
    <organization>COSAH</organization>
  </responsible_party>
  <keyword>patients without comorbidity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

